GlassScriptPhysician profile
Yasser Kabbani
NPI 1982050142
$1,430.89
in general payments reported to CMS, 2019-2025
10 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $103 · 2023: $440 · 2024: $468 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.00 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,014.64 | 2022-2025 | |
| Inari Medical, INC. | $150.76 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Emd Serono, INC. | $84.01 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $37.58 | 2024 | |
| Biogen, INC. | $33.22 | 2023 | Spinraza, Spinraza |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2024 | Hyqvia |
| Neurelis, INC. | $25.25 | 2023 | Valtoco |
| Supernus Pharmaceuticals, INC. | $23.52 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Amgen INC. | $14.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Kabbani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.